ALK-Abelló (ALK) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
5 Jan, 2026Opening remarks and agenda
AGM was legally convened with 99% of votes and share capital represented, ensuring broad support for agenda proposals.
Agenda included reports on activities, approval of annual report, profit allocation, remuneration, board elections, auditor appointment, and other business.
Financial performance review
Revenue grew by 15% in local currencies, reaching over DKK 5.5 billion, with EBIT margin rising to 20%.
Operating profit exceeded DKK 1.1 billion, the best result ever, driven by strong tablet sales and cost control.
Cash flow from operations was DKK 1.2 billion, and tablet sales grew 24%.
2025 guidance expects 9–13% revenue growth and EBIT margin around 25%.
Board and executive committee updates
Board held 13 meetings and several committee sessions, focusing on new strategy and self-evaluation.
Remuneration for management increased due to performance, with total board remuneration at DKK 41 million.
Board activity level was high, and a fee increase for 2025 was proposed to attract expertise.
Latest events from ALK-Abelló
- Record growth, resumed dividend, and all board proposals approved amid strategic expansion.ALK
AGM 202616 Mar 2026 - Revenue up 15% and EBIT margin at 26%, led by tablet and anaphylaxis product growth.ALK
Q4 202520 Feb 2026 - Revenue up 15% and EBIT margin at 26%, driven by tablets and anaphylaxis growth.ALK
Q4 202520 Feb 2026 - Aims to double patient reach by 2030, sustain ≥10% growth, and achieve a 25% EBIT margin.ALK
CMD 202431 Jan 2026 - Q2 revenue up 21% and EBIT margin at 19%, driving upgraded 2024 outlook and strong tablet sales.ALK
Q2 202423 Jan 2026 - Exclusive neffy® in-licensing accelerates needle-free anaphylaxis care and portfolio growth.ALK
Investor Update15 Jan 2026 - Q3 revenue up 18% and EBIT margin at 23%, with neffyⓇ deal fueling future growth.ALK
Q3 202414 Jan 2026 - Record revenue and EBIT growth, with strong 2025 outlook driven by tablets and new launches.ALK
Q4 202419 Dec 2025 - Q2 revenue up 12% and EBIT up 41%, with upgraded outlook and strong pediatric launches.ALK
Q2 202523 Nov 2025